Compare Stocks: BDTX, AVTE, PRTA, and PRTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.50 -0.6%	$17.15	$89.95 ▼ $99.05	$420.28M	0.95	53,591 shs	477,455 shs
BDTX Black Diamond Therapeutics	$1.75 +3.6%	$1.97	$1.60 ▼ $4.94	N/A	N/A	N/A	1.10 million shs
PRTA Prothena	$8.81 +4.9%	$8.78	$7.73 ▼ $11.80	N/A	N/A	N/A	654,349 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	+8.31%	+1.18%	-26.87%	+45.90%
BDTX Black Diamond Therapeutics	-10.11%	-6.63%	-10.11%	-3.98%	-57.00%
PRTA Prothena	+2.44%	-0.94%	+1.33%	-1.87%	-14.46%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-0.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$14.50 -0.6%	$17.15	$89.95 ▼ $99.05	$420.28M	0.95	53,591 shs	477,455 shs
BDTX Black Diamond Therapeutics	$1.75 +3.6%	$1.97	$1.60 ▼ $4.94	N/A	N/A	N/A	1.10 million shs
PRTA Prothena	$8.81 +4.9%	$8.78	$7.73 ▼ $11.80	N/A	N/A	N/A	654,349 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	+8.31%	+1.18%	-26.87%	+45.90%
BDTX Black Diamond Therapeutics	-10.11%	-6.63%	-10.11%	-3.98%	-57.00%
PRTA Prothena	+2.44%	-0.94%	+1.33%	-1.87%	-14.46%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	-0.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	2.60	Moderate Buy	$11.00	528.57% Upside
PRTA Prothena	2.75	Moderate Buy	$24.57	178.90% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BDTX, AVTE, PRTA, and PRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/14/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/9/2026	BDTX Black Diamond Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/24/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/6/2026	BDTX Black Diamond Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
BDTX Black Diamond Therapeutics	N/A	-$0.75	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
PRTA Prothena	N/A	-$0.84	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BDTX, AVTE, PRTA, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	BDTX Black Diamond Therapeutics	-$0.0550	N/A	N/A	N/A	$8.33 million	N/A
11/5/2026	Q3 2026	PRTA Prothena	-$0.21	N/A	N/A	N/A	$9.58 million	N/A
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
BDTX Black Diamond Therapeutics	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A
PRTC PureTech Health	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
BDTX Black Diamond Therapeutics	95.47%
PRTA Prothena	97.08%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
BDTX Black Diamond Therapeutics	9.29%
PRTA Prothena	10.40%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
BDTX Black Diamond Therapeutics	21	N/A	52.12 million	Optionable
PRTA Prothena	67	N/A	46.91 million	Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable

BDTX, AVTE, PRTA, and PRTC Headlines

Recent News About These Companies

PureTech (LSE:PRTC) Faces a Key ESMO Test Beyond FTSE 100

October 22, 2026 | kalkinemedia.comK

PRTC's Gallop to Present Ph1b LYT-200 Data at ESMO

October 19, 2026 | markets.ft.com

PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP

October 11, 2026 | markets.ft.com

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of ...

October 9, 2026 | finance.yahoo.com

Tang Capital Management Boosts PureTech Health (PRTC) Stake to 7.08% After Recent Share Purchase

September 27, 2026 | kalkinemedia.comK

PureTech Health tries a lower-risk model

September 22, 2026 | investorschronicle.co.uk

PureTech Health (PRTC) Rises After FDA Fast Track for Blood-Cancer Drug LYT-200

September 21, 2026 | asktraders.comA

PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R ...

September 21, 2026 | streetinsider.com $https://www.streetinsider.com/Business+Wire/PureTech+Announces+Successful+End-of-Phase+1+Meeting+with+U.S.+Food+and+Drug+Administration+%28FDA%29+and+Receipt+of+Fast+Track+Designation+for+LYT-200+in+RelapsedRefractory+%28RR%29+High-Risk+Myelodysplast/27082098.html$

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...

July 13, 2026 | finance.yahoo.com

PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)

July 13, 2026 | uk.finance.yahoo.com

PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2, 2026 | reuters.com

PureTech Health plc American Depositary Shares (PRTC) Real-Time

July 1, 2026 | nasdaq.com

2 UK shares tipped to more than double my money in 2026!

June 20, 2026 | uk.finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 9, 2026 | finance.yahoo.com

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

May 13, 2026 | businesswire.com

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026 | proactiveinvestors.co.uk

PureTech Announces Annual Results for Year Ended December 31, 2025

April 29, 2026 | businesswire.com

PureTech Health: Notice of Results

April 13, 2026 | businesswire.com

PureTech Gains on Results

April 2, 2026 | baystreet.ca

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

April 2, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, AVTE, PRTA, and PRTC Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$14.50 -0.09 (-0.62%)

As of 10/26/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Black Diamond Therapeutics NASDAQ:BDTX

$1.75 +0.06 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 -0.02 (-1.31%)

As of 07:50 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Prothena NASDAQ:PRTA

$8.81 +0.41 (+4.88%)

Closing price 04:00 PM Eastern

Extended Trading

$8.82 +0.01 (+0.17%)

As of 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 10/26/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDTX, AVTE, PRTA, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDTX, AVTE, PRTA, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDTX, AVTE, PRTA, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, AVTE, PRTA, and PRTC Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Black Diamond Therapeutics NASDAQ:BDTX

Prothena NASDAQ:PRTA

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDTX, AVTE, PRTA, and PRTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDTX, AVTE, PRTA, and PRTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDTX, AVTE, PRTA, and PRTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX, AVTE, PRTA, and PRTC Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Black Diamond Therapeutics NASDAQ:BDTX

Prothena NASDAQ:PRTA

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools